Trial Profile
Randomized, Double-blind, Placebo-controlled Study of the Effect of Cerebrolysin (EVER Neuro Pharma GmbH, Austria) at the Level of Paresis of the Upper Limb When Used in Complex Therapy of Acute Ischemic Stroke
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Oct 2017
Price :
$35
*
At a glance
- Drugs FPF 1070 (Primary)
- Indications Stroke
- Focus Therapeutic Use
- 27 Oct 2015 New trial record